Efficacy and Safety of PD-1 Inhibitors and Targeted Drugs Combined with Radiotherapy in First-Line Treatment of Oligometastatic Hepatocellular Carcinoma

被引：0
|
作者：
Zhu, K. [1 ]
Liu, J. [2 ]
Dou, X. [1 ]
Zhang, X. [1 ]
Xu, L. [1 ]
Shi, P. [2 ]
Shi, F. [1 ]
Yue, J. [1 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Shandong First Med Univ, Shandong Canc Hosp, Jinan, Shandong, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3126
引用
收藏
页码：E509 / E509
页数：1
相关论文
共 50 条
  • [21] Clinical efficacy of HAIC (FOLFOX) combined with tyrosine kinase inhibitors plus PD-1 inhibitors vs. HAIC combined with bevacizumab plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma
    Zhu, Wenwen
    Zhang, Ningning
    Lu, Wei
    Zhang, Yiyan
    Liu, Kaipeng
    Liu, Huiru
    JOURNAL OF HEPATOLOGY, 2024, 80 : S454 - S455
  • [22] First-line PD-1 Inhibitors and Chemotherapy Combined with or without Radiotherapy in Advanced Non-small-cell Lung Cancer
    Ding, P.
    Huang, Y.
    Tong, F.
    Chen, L.
    Wen, L.
    Zhang, R.
    Cheng, S.
    Dong, X.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S75 - S75
  • [23] Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysis
    Xian, F.
    Wu, J.
    Yuan, Y-l.
    Bie, J.
    Xu, G. -h.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (04) : 1494 - 1502
  • [24] Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer
    Yu, Hui
    Chen, Ping
    Cai, Xiuyu
    Chen, Chen
    Zhang, Xuanye
    He, Lina
    Zhou, Yixin
    Hong, Shaodong
    Zhang, Bei
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (03) : 637 - 644
  • [25] Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer
    Hui Yu
    Ping Chen
    Xiuyu Cai
    Chen Chen
    Xuanye Zhang
    Lina He
    Yixin Zhou
    Shaodong Hong
    Bei Zhang
    Cancer Immunology, Immunotherapy, 2022, 71 : 637 - 644
  • [26] Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors
    Bei, Weixin
    Dong, Shuhui
    Liu, Guoying
    Lin, Lanfeng
    Jiang, Yaofei
    Lu, Nian
    Li, Wangzhong
    Liang, Hu
    Xiang, Yanqun
    Xia, Weixiong
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 771 - 780
  • [27] Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis
    Xu, Kai
    Yu, Man
    Sun, Qingli
    Zhang, Lingli
    Qian, Xiaodan
    Su, Dan
    Gong, Jinhong
    Shang, Jingjing
    Lin, Yingtao
    Li, Xin
    ANNALS OF MEDICINE, 2025, 57 (01)
  • [28] Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis
    Li, Zi-Chun
    Sun, Yu-Ting
    Lai, Ming-Yu
    Zhou, Yi-Xin
    Qiu, Miao-Zhen
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 109
  • [29] PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
    Jia Zhao
    Simeng Zhang
    Xiaoyu Guo
    Ce li
    Bowen Yang
    Xiujuan Qu
    Shuo Wang
    BMC Cancer, 23
  • [30] PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
    Zhao, Jia
    Zhang, Simeng
    Guo, Xiaoyu
    Li, Ce
    Yang, Bowen
    Qu, Xiujuan
    Wang, Shuo
    BMC CANCER, 2023, 23 (01)
12345